Affiliation:
1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland
Abstract
Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mutations are among the most commonly found oncogenic alterations in non-small cell lung cancer (NSCLC) patients. Unfortunately, KRAS mutations have been considered “undruggable” for many years, making treatment options very limited. Immunotherapy targeting programmed death-ligand 1 (PD-L1), programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has emerged as a promising therapeutic option for NSCLC patients. However, some studies have suggested a lower response rate to immunotherapy in KRAS-mutated NSCLC patients with the coexistence of mutations in the STK11 (Serine/Threonine Kinase 11) gene. However, recent clinical trials have shown promising results with the combination of immunotherapy and chemotherapy or immunotherapy and KRAS inhibitors (sotorasib, adagrasib) in such patients. In other studies, the high efficacy of immunotherapy has been demonstrated in NSCLC patients with mutations in the KRAS gene that do not coexist with other mutations or coexist with the TP53 gene mutations. In this paper, we review the available literature on the efficacy of immunotherapy in KRAS-mutated NSCLC patients. In addition, we presented single-site experience on the efficacy of immunotherapy in NSCLC patients with KRAS mutations. The effectiveness of chemoimmunotherapy or immunotherapy as well as KRAS inhibitors extends the overall survival of advanced NSCLC patients with the G12C mutation in the KRAS gene to 2–3 years. This type of management has become the new standard in the treatment of NSCLC patients. Further studies are needed to clarify the potential benefits of immunotherapy in KRAS-mutated NSCLC patients and to identify potential biomarkers that may help predict response to therapy.
Reference71 articles.
1. Cancer (IARC) (2022, December 29). T.I.A. for R. on Global Cancer Observatory. Available online: https://gco.iarc.fr/.
2. Cancer Statistics, 2021;Siegel;CA Cancer J. Clin.,2021
3. The 2021 WHO Classification of Lung Tumors: Impact of Advances since 2015;Nicholson;J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer,2022
4. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients;Wang;J. Cancer Res. Clin. Oncol.,2020
5. (2023, May 19). SEER Cancer Statistics Review, 1975–2018, Available online: https://seer.cancer.gov/csr/1975_2018/index.html.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献